Evidence map›Paper›PMID 42580461›Full record

ArticleNeuroImage2026

High-field MRI correlates with immunohistochemical analysis of the normal and Alzheimer's disease anterior olfactory nucleus.

Helen C Murray, Birger Victor Dieriks, Stephen Dodd, Ted Usdin, Danica Hamlin, Blake Highet, Zachary Sit, Minji Kim, Richard Faull, Clinton Turner and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Helen C MurrayDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand; Laboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: h.murray@auckland.ac.nz.
Birger Victor DieriksDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: v.dieriks@auckland.ac.nz.
Stephen DoddLaboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: doddst@ninds.nih.gov.
Ted UsdinSystems Neuroscience Imaging Resource, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: usdint@mail.nih.gov.
Danica HamlinDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: danica.hamlin@auckland.ac.nz.
Blake HighetDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: blake.highet@auckland.ac.nz.
Zachary SitDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: zachary.sit@auckland.ac.nz.
Minji KimDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: mkim538@aucklanduni.ac.nz.
Richard FaullDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: rlm.faull@auckland.ac.nz.
Clinton TurnerDepartment of Anatomical Pathology, Pathology and Laboratory Medicine, Auckland City Hospital, Auckland, 1023, New Zealand.
Miriam ScadengDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: m.scadeng@auckland.ac.nz.
Maurice A CurtisDepartment of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, 1023, New Zealand. Electronic address: m.curtis@auckland.ac.nz.
Alan KoretskyLaboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: KoretskyA@ninds.nih.gov.

Funding

MRI contrast for molecular and cellular imaging of the brainZIANS003047 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI KORETSKY, ALAN · 2009 to 2025
$29.3M
Systems Neuroscience Imaging ResourceZICMH002963 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI USDIN, THEODORE · 2017 to 2025
$18.0M
Intramural NIH HHS ZIA NS003047Intramural NIH HHS ZIC MH002963
6 · The paper itself

Abstract

The human anterior olfactory nucleus (AON) is one of the earliest brain regions affected by tau and beta amyloid pathology in Alzheimer's disease, potentially serving as a conduit for the spread of aggregated proteins to downstream cortical regions. However, the architecture of the human AON remains poorly understood. Here, we applied a multimodal imaging framework combining ultra-high-field magnetic resonance (MR) microscopy, thin-section immunofluorescence, and whole-mount tissue clearing with confocal and light-sheet microscopy to characterise the three-dimensional architecture of the AON and its involvement in Alzheimer's disease (AD). In neurologically normal cases, we identified tear-shaped AON clusters using MR microscopy that aligned with cytoarchitectural boundaries defined by PGP9.5, CNPase, and UEA lectin immunolabelling in serial sections, confirming the validity of AON segmentation in intact bulbs. In AD cases, MR microscopy, immunofluorescence, and light-sheet imaging revealed concentrated tau and beta-amyloid pathology within the AON clusters. Despite this pathology burden, neither total olfactory bulb volume nor AON volume differed significantly between neurologically normal and AD groups, and pathology load did not correlate with either volumetric measure. These findings refine our understanding of the human olfactory bulb and AON structure and demonstrate that high-resolution MR microscopy is a reliable tool for investigating substructural changes in the olfactory system.

Indexed as

Alzheimer DiseaseMagnetic Resonance ImagingOlfactory BulbOlfactory PathwaysAgedAged, 80 and overAmyloid beta-PeptidesFemaleHumansImmunohistochemistryMaleMiddle Agedtau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer’s diseaseAnterior olfactory nucleusMagnetic resonance microscopyOlfactory bulb

Identifiers

PMID42580461
PMCPMC13526416

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.